CIT Clinical Trials - Actively Enrolling

SLE

• Immune Tolerance Network (ITN)/Abatacept Study: DBPCRCT of CTLA-4-Ig (abatacept) plus Cytoxan (CTX) versus CTX alone for lupus GN. All pts receive azathioprine therapy for 16 weeks.
• Genentech / anti-IFN mAb: DBPCRCT of an anti-interferon mAb in patients with moderately active SLE (not renal or CNS)

Rheumatoid Arthritis

• Sanofi-Aventis: DBPCRCT of a new anti-IL-6 R mAb in RA patients on MTX; past TNF-I OK).
• Roche / TCZ in Early RA: DBPCRCT of tocilizumab in patients with early RA (naïve to MTX, TNFI)
• Pfizer Tasocitinib (novel JAK inhibitor): 2 DBPCRCT studies – 1 in early RA, 1 in established RA (a biopsy study); both have lonig-term open label extension
• Amgen: novel IL-17 inhibitor in biologic-naïve patients with active RA on MTX; 3 year open label treatment planned

Psoriatic Arthritis

• Centocor / ustekinumab in PsA: DBPCRCT of an anti-IL-12/anti-IL-23 mAb in patients with active PsA (must be TNF-I naïve)

Gout

• Ardea and Nuon: two studies of new uricosurics to be added to allopurinol in patients with gout and a uric acid > 6 mg/dL

Ankylosing Spondylitis

• Sanofi-Aventis: DBPCRCT of a new anti-IL-6 R mAb in AS; past TNF-I OK